308: Ignite Session 3B

Presentations:

• 9:00 AM – 9:05 AM Eastern Time

  Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
  

  Ignite Speaker: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
• 9:05 AM – 9:10 AM Eastern Time

  Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain
  

  Ignite Speaker: Cristina Valero, MD – Hospital de la Princesa
• 9:10 AM – 9:15 AM Eastern Time

  Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
  

  Ignite Speaker: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
• 9:15 AM – 9:20 AM Eastern Time

  Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
  

  Ignite Speaker: Atul Deodhar, MD – Oregon Health & Science University
• 9:20 AM – 9:25 AM Eastern Time

  Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
  

  Ignite Speaker: Laure Gossec, MD, PhD – Sorbonne Universite
• 9:25 AM – 9:30 AM Eastern Time

  Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
  

  Ignite Speaker: Saakshi Khattri, MD, MBBS – Mount Sinai Medical Center
• 9:30 AM – 9:35 AM Eastern Time

  Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
  

  Ignite Speaker: William Tillett, MD, PhD – Royal National Hospital for rheumatic diseases
• 9:35 AM – 9:40 AM Eastern Time

  Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
  

  Ignite Speaker: William Tillett, MD, PhD – Royal National Hospital for rheumatic diseases
• 9:40 AM – 9:45 AM Eastern Time

  WITHDRAWN
• 9:45 AM – 9:50 AM Eastern Time

  Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
  

  Ignite Speaker: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health